Chronic myeloid leukemia

Reading File

Finding Sources

Searching PubMed

"chronic myeloid leukemia" AND treatment

Reading File

Loading Image

Reading File

Loading Image

Reading File

Excellent - I now have comprehensive content covering pathogenesis, morphology, clinical features, phases, TKI therapy, milestones, and prognosis. I have enough to write a thorough, well-structured response.

Chronic Myeloid Leukemia (CML)

Overview

Chronic myeloid leukemia is a clonal hematopoietic stem cell neoplasm and the prototypical myeloproliferative disorder. Its entire pathobiology is driven by a single defining molecular event: the BCR::ABL1 fusion oncogene. Before tyrosine kinase inhibitors (TKIs), the median survival was 3-7 years; today, with modern TKI therapy, the 10-year survival exceeds 85% and approaches that of an age-matched general population.

Molecular Pathogenesis

The defining event is a reciprocal translocation between chromosomes 9 and 22: t(9;22)(q34.1;q11.2), creating the Philadelphia (Ph) chromosome (shortened chromosome 22). This juxtaposes the ABL1 proto-oncogene from chromosome 9 with the BCR gene on chromosome 22, generating the chimeric BCR::ABL1 oncogene.

Pathogenesis of CML - BCR::ABL fusion gene formation and downstream signaling (Robbins Pathology)

The BCR moiety contains a dimerization domain that self-associates, leading to constitutive activation of the ABL tyrosine kinase. This oncoprotein (p210 BCR-ABL, 210 kDa) then phosphorylates downstream targets activating the RAS, JAK/STAT, and AKT pathways - driving growth factor-independent proliferation and survival while preserving normal differentiation. The net result is a massive increase in mature granulocytes and platelets in the blood. The cell of origin is a pluripotent hematopoietic stem cell (HSC), explaining why both myeloid and lymphoid lineages can be involved.

The Ph chromosome is present in >90% of cases; the remaining ~10% have cryptic BCR::ABL1 rearrangements detectable only by FISH or PCR.
Two main transcript variants exist: e13a2 (b2a2) and e14a2 (b3a2), both encoding p210.
The p190 isoform (from minor BCR breakpoint) is rare in CML but common in Ph+ ALL.
There is no BCR-ABL1-negative CML - diseases formerly called this are distinct entities (atypical CML, chronic neutrophilic leukemia).

(Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 583; Harrison's Principles of Internal Medicine 22E, p. 878)

Epidemiology

Parameter	Data
Proportion of all leukemias	~15%
Annual incidence (US)	~9,000 cases/year; 2 per 100,000
Worldwide annual incidence	~250,000 cases
Median age at diagnosis	55-65 years
Male:female ratio	1.6:1
Pediatric cases	Only 3% are <20 years

With TKI therapy reducing annual mortality from 10-20% to ~1-2%, CML prevalence is projected to plateau at ~450,000 in the US by 2040.

Risk factors are minimal. Ionizing radiation (nuclear accidents, high-dose radiation therapy) increases risk, peaking 5-10 years post-exposure. No associations with benzene, viruses, or familial clustering.

(Harrison's 22E, p. 878)

Disease Phases

CML follows a biphasic or triphasic natural history. Phase definitions differ slightly between the WHO and European Leukemia Network (ELN) classifications:

Chronic Phase (CP)

75% of CML diagnoses are made here
Indolent, dominated by granulocytic proliferation
Peripheral blood blasts <10% (WHO) / <15% (ELN)
Responds well to TKI therapy

Accelerated Phase (AP)

Increasing resistance to therapy
ELN criteria: peripheral/BM blasts 15-30%; additional cytogenetic clones (e.g., trisomy 8, isochromosome 17q, Ph duplication)
WHO criteria: blasts 10-20%
Increasing anemia, thrombocytopenia, rising basophil count

Blast Phase / Blast Crisis (BP)

ELN: blasts ≥30%; WHO: blasts ≥20%
Behaves like acute leukemia
Myeloid blast crisis in ~70% of cases
Lymphoid (pre-B cell) blast crisis in ~25-30%
The lymphoid subtype implicates IKZF1 (Ikaros) mutations in ~85% of cases, same mutations seen in BCR-ABL+ B-ALL

Without treatment: ~50% progress through the accelerated phase over ~3 years; the other 50% transform directly to blast crisis.

(Goldman-Cecil Medicine, p. 1938; Robbins Pathology, p. 583-584)

Morphology

Peripheral Blood:

Leukocytosis often exceeding 100,000 cells/μL, predominantly neutrophils, band forms, metamyelocytes, myelocytes
Elevated eosinophils and basophils
Thrombocytosis (often marked)
Blasts <10% in chronic phase
Low leukocyte alkaline phosphatase (LAP) score - a classic finding

Bone Marrow:

Markedly hypercellular with massively increased maturing granulocytic precursors
Increased small, dysplastic megakaryocytes
Erythroid progenitors normal or mildly decreased
Sea-blue histiocytes (macrophages with wrinkled greenish cytoplasm) - a characteristic finding
Increased reticulin; overt fibrosis is rare in chronic phase

Spleen:

Often massively enlarged due to extramedullary hematopoiesis (can exceed 2,600 g vs. normal ~150-200 g)
Contains infarcts of varying age

(Robbins Pathology, p. 583)

Clinical Features

Onset is insidious; many patients are diagnosed incidentally on routine CBC
Constitutional symptoms from hypermetabolism: fatigue, weakness, weight loss, anorexia, night sweats
Splenomegaly - often massive; can cause dragging sensation in left upper quadrant or acute pain from splenic infarction
Mild-to-moderate anemia
Rarely: hyperviscosity symptoms, gout (urate overproduction), priapism

Differentiation from other myeloproliferative neoplasms rests on detection of BCR::ABL1 by cytogenetics, FISH, or PCR - not on morphology alone.

Diagnosis

A stepwise approach is required:

CBC + differential - leukocytosis with left shift, basophilia, thrombocytosis
Peripheral blood smear - granulocyte spectrum, basophils
Bone marrow biopsy/aspirate - cellularity, blast%, fibrosis
Cytogenetics (karyotype) - identify Ph chromosome t(9;22)
FISH - detects Ph-negative BCR::ABL1-positive cases
Quantitative RT-PCR (qRT-PCR) - quantifies BCR::ABL1 transcript level on the International Scale (IS); baseline and for monitoring response

Treatment

Tyrosine Kinase Inhibitors (TKIs) - The Cornerstone

Six FDA-approved oral BCR::ABL1 TKIs exist:

Agent	Generation	Dose (frontline)	Notable Toxicities
Imatinib (Gleevec)	1st	400 mg daily	Edema, nausea, musculoskeletal pain, rash
Dasatinib (Sprycel)	2nd	100 mg daily	Pleural/pericardial effusions, pulmonary hypertension, myelosuppression
Nilotinib (Tasigna)	2nd	300 mg twice daily	Diabetes, arterio-occlusive events, pancreatitis
Bosutinib (Bosulif)	2nd	400 mg daily	Diarrhea, liver toxicity, renal dysfunction
Ponatinib (Iclusig)	3rd	45 mg daily (reduce to 15 mg once CCyR)	Arterio-occlusive events (10-20%), hypertension, pancreatitis
Asciminib (Scemblix)	3rd / STAMP inhibitor	40 mg twice daily	Arterial occlusive events, hypertension

Key points:

Nilotinib is structurally similar to imatinib but 30x more potent
Dasatinib is 300x more potent than imatinib and also inhibits SRC kinases
Bosutinib is 30-50x more potent than imatinib and also inhibits SRC kinases
Ponatinib and asciminib are indicated for T315I-mutated CML (the "gatekeeper" mutation that confers resistance to all 1st/2nd generation TKIs)
Asciminib (STAMP inhibitor) binds the ABL myristoyl pocket - a completely different binding site from all other TKIs, making it uniquely active against many resistance mutations
Omacetaxine (Synribo) - a non-TKI option (protein synthesis inhibitor) for patients failing ≥2 TKIs

(Harrison's 22E, pp. 882-883)

Monitoring and Response Milestones

Response is monitored by qRT-PCR (BCR::ABL1 IS) and cytogenetics. Key definitions:

Response	Definition
Complete Hematologic Response (CHR)	Normal CBC, no symptoms, spleen normal
Complete Cytogenetic Response (CCyR)	0% Ph+ metaphases on karyotype
Major Molecular Response (MMR / MR3.0)	BCR::ABL1 IS ≤0.1% (3-log reduction)
MR4.0 / Deep Molecular Response	BCR::ABL1 IS ≤0.01%
MR4.5	BCR::ABL1 IS ≤0.0032%

ELN and NCCN define "failure" and "warning" milestones at 3, 6, 12 months - guiding when to switch TKIs.

Treatment-Free Remission (TFR)

A major emerging concept: patients achieving sustained deep molecular response (MR4.0 or MR4.5 for ≥2 years) may attempt TKI discontinuation. Approximately 40-60% maintain remission off therapy long-term. Monthly PCR monitoring is mandatory after stopping; ~50% who lose MMR regain it after restarting the same TKI.

Allogeneic HSCT

Previously the only curative option, now reserved for:

Blast phase or accelerated phase
TKI resistance/failure after multiple lines
T315I mutation not responsive to ponatinib/asciminib
Healthy, younger patients with high-risk disease

ABL1 Kinase Domain Mutations and Resistance

When patients fail TKI therapy, ~50% of cases are due to point mutations in the ABL1 kinase domain preventing TKI binding (e.g., T315I). Testing for mutations guides selection of the next TKI. The other ~50% involve BCR::ABL1-independent resistance mechanisms (other kinase mutations, BCR::ABL1 amplification, clonal evolution).

Prognosis

Survival in CML by era of therapy (MD Anderson, Harrison's 22E)

Chronic phase with TKIs: 10-year survival >85%, approaching normal life expectancy. In the TKI era (2001-present), only 22 out of 597 patients died from CML-related causes at 10 years (survival ~95% for CML-specific death).
Accelerated phase with TKIs: Median survival improved from 28 months (pre-TKI era) to 88 months.
Blast crisis: Remains very poor; median survival only 5-7 months even in the TKI era.

Prognostic scoring systems (Sokal, Hasford/Euro, EUTOS, ELTS) stratify patients at diagnosis into low/intermediate/high risk, though their relevance has diminished with effective TKI therapy.

Key Distinguishing Points

Feature	CML
Genetic lesion	BCR::ABL1 (Ph chromosome), 100% of cases
Oncoprotein	p210 BCR-ABL (constitutive tyrosine kinase)
LAP score	Low (distinguishes from leukemoid reaction)
Basophilia	Characteristic; basophil count predicts transformation
Targeted therapy	BCR::ABL1 TKIs - imatinib, nilotinib, dasatinib, bosutinib, ponatinib, asciminib
Blast crisis type	Myeloid 70%, lymphoid ~25-30%
Curative option	Allogeneic HSCT (now late-line only)

Sources: Robbins, Cotran & Kumar Pathologic Basis of Disease pp. 582-585 | Harrison's Principles of Internal Medicine 22E pp. 878-884 | Goldman-Cecil Medicine pp. 1938-1940

Recent evidence note: A 2024 systematic review (PMID 39634261) comparing ponatinib vs. asciminib after 2nd-generation TKI failure found broadly comparable outcomes, supporting asciminib as a viable option in this setting - consistent with current guidelines. A 2025 meta-analysis (PMID 40317312) systematically documented patient-reported TKI toxicity symptoms, reinforcing the clinical importance of TKI side effect monitoring and dose optimization.

This is a shared conversation. Sign in to Orris to start your own chat.